AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
Factors predictive of outcome in patients with breast cancer refractory toneoadjuvant chemotherapy
Authors: Buchholz, TA Hill, BS Tucker, SL Frye, DK Kuerer, HM Buzdar, AU McNeese, MD Singletary, SE Ueno, NT Pusztai, L Valero, V Hortobagyi, GN
Citation: Ta. Buchholz et al., Factors predictive of outcome in patients with breast cancer refractory toneoadjuvant chemotherapy, CANCER J, 7(5), 2001, pp. 413-420
Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation
Authors: Ibrahim, NK Valero, V Rahman, Z Theriault, RL Walters, RS Buzdar, AU Booser, DJ Holmes, FA Murray, DJ Willey, J Bast, R Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation, CANCER INV, 19(5), 2001, pp. 459-466
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer
Authors: Rivera, E Valero, V Syrewicz, L Rahman, Z Esteva, FL Theriault, RL Rosales, MM Booser, D Murray, JL Bast, RC Hortobagyi, GN
Citation: E. Rivera et al., Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer, J CL ONCOL, 19(6), 2001, pp. 1716-1722
Long-term results of combined-modality therapy for locally advanced breastcancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience
Authors: Brito, RA Valero, V Buzdar, AU Booser, DJ Ames, F Strom, E Ross, M Theriault, RL Frye, D Kau, SW Asmar, L McNeese, M Singletary, SE Hortobagyi, GN
Citation: Ra. Brito et al., Long-term results of combined-modality therapy for locally advanced breastcancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience, J CL ONCOL, 19(3), 2001, pp. 628-633
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial
Authors: Hortobagyi, GN Ueno, NT Xia, WY Zhang, S Wolf, JK Putnam, JB Weiden, PL Willey, JS Carey, M Branham, DL Payne, JY Tucker, SD Bartholomeusz, C Kilbourn, RG De Jager, RL Sneige, N Katz, RL Anklesaria, P Ibrahim, NK Murray, JL Theriault, RL Valero, V Gershenson, DM Bevers, MW Huang, L Lopez-Berestein, G Hung, MC
Citation: Gn. Hortobagyi et al., Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial, J CL ONCOL, 19(14), 2001, pp. 3422-3433
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
Authors: Seidman, AD Fornier, MN Esteva, FJ Tan, L Kaptain, S Bach, A Panageas, KS Arroyo, C Valero, V Currie, V Gilewski, T Theodoulou, M Moynahan, ME Moasser, M Sklarin, N Dickler, M D'Andrea, G Cristofanilli, M Rivera, E Hortobagyi, GN Norton, L Hudis, CA
Citation: Ad. Seidman et al., Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification, J CL ONCOL, 19(10), 2001, pp. 2587-2595
Canalicular stenosis secondary to docetaxel (Taxotere) - A newly recognized side effect
Authors: Esmaeli, B Valero, V Ahmadi, MA Booser, D
Citation: B. Esmaeli et al., Canalicular stenosis secondary to docetaxel (Taxotere) - A newly recognized side effect, OPHTHALMOL, 108(5), 2001, pp. 994-995
Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects
Authors: Valero, V Perez, E Dieras, V
Citation: V. Valero et al., Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects, SEMIN ONCOL, 28(4), 2001, pp. 15-23
A process algebra for probabilistic and nondeterministic processes
Authors: Cazorla, D Cuartero, F Valero, V Pelayo, FL
Citation: D. Cazorla et al., A process algebra for probabilistic and nondeterministic processes, INF PROCESS, 80(1), 2001, pp. 15-23
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma
Authors: Cristofanilli, M Buzdar, AU Sneige, N Smith, T Wasaff, B Ibrahim, N Booser, D Rivera, E Murray, JL Valero, V Ueno, N Singletary, ES Hunt, K Strom, E McNeese, M Stelling, C Hortobagyi, GN
Citation: M. Cristofanilli et al., Paclitaxel in the multimodality treatment for inflammatory breast carcinoma, CANCER, 92(7), 2001, pp. 1775-1782
Female patients with breast carcinoma age 30 years and younger have a poorprognosis - The M. D. Anderson Cancer Center Experience
Authors: Xiong, QH Valero, V Kau, V Kau, SW Taylor, S Smith, TL Smith, TL Buzdar, AU Hortobagyi, GN Theriault, RL
Citation: Qh. Xiong et al., Female patients with breast carcinoma age 30 years and younger have a poorprognosis - The M. D. Anderson Cancer Center Experience, CANCER, 92(10), 2001, pp. 2523-2528
Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma
Authors: Ibrahim, NK Buzdar, AU Valero, V Dhingra, K Willey, J Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma, CANCER, 91(4), 2001, pp. 664-671
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
Authors: Hortobagyi, GN Buzdar, AU Theriault, RL Valero, V Frye, D Booser, DJ Holmes, FA Giralt, S Khouri, I Andersson, B Gajewski, JL Rondon, G Smith, TL Singletary, SE Ames, FC Sneige, N Strom, EA McNeese, MD Deisseroth, AB Champlin, RE
Citation: Gn. Hortobagyi et al., Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma, J NAT CANC, 92(3), 2000, pp. 225-233
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer
Authors: Ibrahim, NK Valero, V Theriault, RL Willey, J Walters, RS Buzdar, AU Booser, DJ Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer, AM J CL ONC, 23(2), 2000, pp. 117-121
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer
Authors: Ibrahim, NK Sahin, AA Dubrow, RA Lynch, PN Boehnke-Michaud, L Valero, V Buzdar, AU Hortobagyi, GN
Citation: Nk. Ibrahim et al., Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer, LANCET, 355(9200), 2000, pp. 281-283
Risks and benefits of taxanes in breast and ovarian cancer
Authors: Michaud, LB Valero, V Hortobagyi, G
Citation: Lb. Michaud et al., Risks and benefits of taxanes in breast and ovarian cancer, DRUG SAFETY, 23(5), 2000, pp. 401-428
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
Authors: Rivera, E Holmes, FA Frye, D Valero, V Theriault, RL Booser, D Walters, R Buzdar, AU Dhingra, K Fraschini, G Hortobagyi, GN
Citation: E. Rivera et al., Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy, CANCER, 89(11), 2000, pp. 2195-2201
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy
Authors: Hoff, PM Valero, V Buzdar, AU Singletary, SE Theriault, RL Booser, D Asmar, L Frye, D McNeese, MD Hortobagyi, GN
Citation: Pm. Hoff et al., Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy, CANCER, 88(9), 2000, pp. 2054-2060
Minority cancer patients and their providers - Pain management attitudes and practice
Authors: Anderson, KC Mendoza, TR Valero, V Richman, SP Russell, C Hurley, J DeLeon, G Washington, P Palos, G Payne, R Cleeland, CS
Citation: Kc. Anderson et al., Minority cancer patients and their providers - Pain management attitudes and practice, CANCER, 88(8), 2000, pp. 1929-1938
A unified definition of clinical anthracycline resistance breast cancer
Authors: Pivot, X Asmar, L Buzdar, AU Valero, V Hortobagyi, G
Citation: X. Pivot et al., A unified definition of clinical anthracycline resistance breast cancer, BR J CANC, 82(3), 2000, pp. 529-534
High calcium concentrations shift the mode of exocytosis to the kiss-and-run mechanism
Authors: Ales, E Tabares, L Poyato, JM Valero, V Lindau, M de Toledo, GA
Citation: E. Ales et al., High calcium concentrations shift the mode of exocytosis to the kiss-and-run mechanism, NAT CELL BI, 1(1), 1999, pp. 40-44
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results
Authors: Holmes, FA Valero, V Walters, RS Theriault, RL Booser, DJ Gibbs, H Fraschini, G Buzdar, AU Willey, J Frye, D Asmar, L Hortobagyi, GN
Citation: Fa. Holmes et al., Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results, ANN ONCOL, 10(4), 1999, pp. 403-411
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, andfluorouracil as first-line therapy in patients with metastatic breast cancer
Authors: Valero, V Buzdar, AU Theriault, RL Azarnia, N Fonseca, GA Willey, J Ewer, M Walters, RS Mackay, B Podoloff, D Booser, D Lee, LW Hortobagyi, GN
Citation: V. Valero et al., Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, andfluorouracil as first-line therapy in patients with metastatic breast cancer, J CL ONCOL, 17(5), 1999, pp. 1425-1434
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
Authors: Buzdar, AU Singletary, SE Theriault, RL Booser, DJ Valero, V Ibrahim, N Smith, TL Asmar, L Frye, D Manuel, N Kau, SW McNeese, M Strom, E Hunt, K Ames, F Hortobagyi, GN
Citation: Au. Buzdar et al., Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer, J CL ONCOL, 17(11), 1999, pp. 3412-3417
Phase I II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience
Authors: Cristofanilli, M Holmes, FA Esparza, L Valero, V Buzdar, AU Neidhart, JA Hortobagyi, GN
Citation: M. Cristofanilli et al., Phase I II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience, BREAST CANC, 54(3), 1999, pp. 225-233
Risultati: 1-25 | 26-28